{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=60",
    "query": {
      "intervention": "placebo",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 33093,
    "total_pages": 3310,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T18:36:30.778Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03703882",
      "title": "Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "Edasalonexent",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catabasis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "7 Years",
        "sex": "MALE",
        "summary": "4 Years to 7 Years · Male only"
      },
      "enrollment_count": 131,
      "start_date": "2018-10-02",
      "completion_date": "2020-09-22",
      "has_results": true,
      "last_update_posted_date": "2022-06-21",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 24,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03703882"
    },
    {
      "nct_id": "NCT02234180",
      "title": "Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Stage IIB Esophageal Adenocarcinoma",
        "Stage IIIA Esophageal Adenocarcinoma",
        "Stage IIIB Esophageal Adenocarcinoma",
        "Stage IIIC Esophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2014-09",
      "completion_date": "2016-06-08",
      "has_results": true,
      "last_update_posted_date": "2018-10-17",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 10,
      "location_summary": "Urbana, Illinois • Wichita, Kansas • New Orleans, Louisiana + 7 more",
      "locations": [
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234180"
    },
    {
      "nct_id": "NCT05637879",
      "title": "Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/pibrentasvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "White River Junction Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "19 Years to 70 Years"
      },
      "enrollment_count": 92,
      "start_date": "2023-12-18",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 1,
      "location_summary": "White River Junction, Vermont",
      "locations": [
        {
          "city": "White River Junction",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05637879"
    },
    {
      "nct_id": "NCT02836496",
      "title": "Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypereosinophilic Syndrome"
      ],
      "interventions": [
        {
          "name": "Mepolizumab 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching mepolizumab",
          "type": "DRUG"
        },
        {
          "name": "Active OCS capsules (5 mg prednisolone or prednisone)",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching OCS capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2017-03-07",
      "completion_date": "2019-08-08",
      "has_results": true,
      "last_update_posted_date": "2020-02-21",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 7,
      "location_summary": "San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Mayfield Heights",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02836496"
    },
    {
      "nct_id": "NCT01127659",
      "title": "Testosterone Replacement in Men With Diabetes and Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "testosterone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "30 Years to 65 Years · Male only"
      },
      "enrollment_count": 137,
      "start_date": "2010-05",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2022-11-29",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 1,
      "location_summary": "Williamsville, New York",
      "locations": [
        {
          "city": "Williamsville",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01127659"
    },
    {
      "nct_id": "NCT04798027",
      "title": "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 mRNA vaccine formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 mRNA vaccine formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 mRNA vaccine formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% normal saline)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2021-03-12",
      "completion_date": "2022-06-27",
      "has_results": true,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 12,
      "location_summary": "Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04798027"
    },
    {
      "nct_id": "NCT05405361",
      "title": "A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multifocal Motor Neuropathy (MMN)"
      ],
      "interventions": [
        {
          "name": "ARGX-117",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2023-01-18",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Glenview, Illinois • Minneapolis, Minnesota + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Glenview",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05405361"
    },
    {
      "nct_id": "NCT05811923",
      "title": "Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome",
        "Caffeine"
      ],
      "interventions": [
        {
          "name": "Venous Blood Collection",
          "type": "OTHER"
        },
        {
          "name": "Resting Metabolic Rate Determination",
          "type": "OTHER"
        },
        {
          "name": "Mood State",
          "type": "OTHER"
        },
        {
          "name": "Visual Analog Scales",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Lindenwood University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-12-12",
      "completion_date": "2022-10-12",
      "has_results": false,
      "last_update_posted_date": "2023-04-13",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05811923"
    },
    {
      "nct_id": "NCT07036523",
      "title": "A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "BI 765423",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2025-11-13",
      "completion_date": "2027-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Gainesville, Florida • Ocala, Florida + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07036523"
    },
    {
      "nct_id": "NCT00414323",
      "title": "Evaluation of the Effects of Duloxetine on Norepinephrine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Duloxetine",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2006-11",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2007-06-12",
      "last_synced_at": "2026-10-24T18:36:30.778Z",
      "location_count": 2,
      "location_summary": "Glendale, California • San Antonio, Texas",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00414323"
    }
  ]
}